Type 2 Diabetes Trial, By Invitation NCT07673822 Sponsor: Novo Nordisk A/S Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Type 2 Diabetes Trial, By Invitation

NCT07673822
By Invitation Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People enrolled in the Korean National Health Insurance Service (NHIS) with valid insurance coverage during the year being assessed (for the main analysis).
  • Adults aged 19 years or older as of January 1 of the relevant assessment year, covering years 2013 to 2023 (for the main analysis).
  • People enrolled in the Korean National Health Insurance Service (NHIS) with valid insurance coverage during the year they enter the study (for the subgroup part of the study).
  • Adults aged 19 years or older as of the date they enter the relevant subgroup part of the study (for the subgroup analysis).
  • People who meet the study's specific definition of one of four pre-specified health conditions or states: metabolic-associated fatty liver disease (MASLD), heart failure (HF), a particular stage of a combined heart-kidney-metabolic condition (CKM stage), or high obesity — as defined in the study plan (confirm with trial site).

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People whose age or sex information is missing from the NHIS database (for the main analysis).
  • People who have not been continuously enrolled in the NHIS for at least one full year before the study start date (for the main analysis).
  • People whose age or sex information is missing from the NHIS database (for the subgroup analysis).
  • People who have not been continuously enrolled in the NHIS for at least one full year before their subgroup study entry date (for the subgroup analysis).
  • People who have a recorded history of the relevant health condition within the one year before their subgroup study entry date (for the subgroup analysis).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
By Invitation
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
8 June 2026
Est. completion
3 August 2026

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Proportion of participants with obesity (BMI ≥25 kilograms per square meter (kg/m^2)); Proportion of participants with T2D; Proportion of participants with hypertension; Proportion of participants with dyslipidemia; Proportion of participants with CVD (ASCVD, HF with atrial fibrillation, HF without atrial fibrillation); Proportion of participants with CKD; Proportion of participants with MASLD; at-risk Metabolic Dysfunction-Associated Steatohepatitis (MASH)(within MASLD); Proportion of participants with Osteoarthritis (OA); Multi-disease overlap (≥2, ≥3 conditions); Patient characteristics in...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov